Energy Tech Nexus has opened in downtown Houston. Photo by Natalie Harms/EnergyCapital

Three Houston energy innovators have cut the ribbon on a new space for energy transition innovation.

The Energy Tech Nexus, located in the historic Niels Esperson Building at the corner of Travis and Rusk Avenue, opened on September 10, which was proclaimed Energy Tech Nexus Day by the city.

Jason Ethier and Juliana Garaizar, formerly in leadership roles at Greentown Labs, teamed up with Nada Ahmed, previously headed innovation and transformation at Aker Solutions, launched ETN as a community for energy transition startups. The new hub plans to host incubation programs, provide mentorship, and open doors to funding and strategic partnerships for its members.

"We are creating more than a space for innovation," Garaizar, who serves as CEO of ETN, says in a news release. "We are crafting a community where pioneers in technology and energy converge to challenge the status quo and accelerate the shift to sustainable energy solutions."

The hub describes its goal of tackling the "trilemma" of energy security, sustainability, and affordability while also contributing to the mission of setting up Houston as the global center for energy transition. To accomplish that mission, ETN will help facilitate rapid deployment of cutting-edge energy technologies.

'The future of energy is not just being written here in Houston; it's being rewritten in more sustainable, efficient, and innovative ways," adds Garaizar. "Houston provides the perfect backdrop for this transformation, offering a rich history in energy and a forward-looking approach to its challenges and opportunities."

"We believe that a broad spectrum of perspectives is crucial in solving global energy challenges. It's about bringing everyone to the table — startups, industry leaders, and investors from all backgrounds," she continues.

Ethier, who co-hosts the Energy Tech Startups Podcast with Ahmed, says he hopes that ETN acts as a meeting place for energy transition innovators.

"By providing the right tools, access, and expertise, we are enabling these companies to leap from ideation to implementation at an unprecedented pace;" Ethier explains. "The interaction between startups and established companies within Energy Tech Nexus creates a unique synergy, fostering innovations that might otherwise take years to mature in isolation."

Payal Patel, an angel investor who has held leadership roles at Station Houston, Plug and Play Ventures, and Softeq, also contributed to launching ETN, which is collaborating with George Liu, who has over 15 years of investment banking experience across energy, cleantech and hardtech with more than $20 billion in M&A projects across his career.

In May, ETN teamed up with Impact Hub Houston to establish the Equitable Energy Transition Alliance and Lab to accelerate startup pilots for underserved communities. The initiative announced that it's won the 2024 U.S. Small Business Administration Growth Accelerator Fund Competition, or GAFC, Stage One award.

ETN celebrated its opening during the inaugural Houston Energy and Climate Week.

------

This article originally ran on EnergyCapital.

Esperson Flex plans on expanding within the historic Niels Esperson Building in the next five years. Photo via espersonflex.com

Historic downtown Houston building plans to expand inclusive coworking for entrepreneurs

moving on up

A nearly 100-year-old building in downtown Houston is welcoming in entrepreneurs, small business owners, and enterprise firms with a new opportunity to innovate outside of traditional office spaces.

Esperson Flex — a coworking concept managed by Cameron Management in The Niels Esperson Building, which has stood out in Houston's skyline since its inception in 1927 — offers various membership tiers in its facility featuring private offices, desk space, conference room, and access to the overall area for freelancers. As an add-on option to the membership, members will have the opportunity to connect with other entrepreneurs through offering reciprocal daily use passes to Cannon members and allow them to book the conference rooms.

“Coworking allows small entrepreneurs to have a community and startup ecosystem that is very cheap and very flexible," Cameron Management CEO Dougal Cameron tells InnovationMap. “They can invest money in their enterprise instead of signing expensive long leases.”

Photo via espersonflex.com

Esperson coworkers have access to The Cannon's digital platform, Cannon Connect, which provides a digital platform for connections, resources, and services to investors, entrepreneurs, startups, and small businesses.

Currently, the offering of the venue is 12,300 square feet and 62 percent of it is leased.The company hopes to expand the coworking facilities to 62,000 square feet in the next five years, according to Cameron.

There are seven groups who are growing their own coworking business under the Esperson and Cameron Management umbrella, and some include working with groups that are specifically targeting often overlooked demographics, including Hispanic, Black, and female entrepreneurs. The Us Space, for instance, is a women of color-focused collective providing support and coworking for its community.

“We believe that entrepreneurship is the answer to many important problems in our world,” Cameron Management CEO Dougal Cameron tells InnovationMap.

In addition, the facility works with the Prison Entrepreneurship Program, which is a comprehensive re-entry program to help empower those trying to change their lives.

Photo via espersonflex.com

Located downtown, Esperson Flex is the latest in flexible work spaces by Cannon, which also include locations in the Energy Corridor, Houston Galleria, Galveston, The Woodlands, and, as of this week, Memorial.

Spaces like Esperson Flex have become increasingly popular for remote workers, and in some cases, have shown increases in overall productivity. In a survey conducted by Airtasker, remote employees worked 1.4 more days every month, than office workers, which equals 16.8 more days every year. In a similar survey by the Gartner 2021 Digital Worker Experience Survey, 43 percent said that flexible working hours helped them achieve more productivity.

The Cannon, too, has seen coworking and community-building opportunities from all corners of Houston, as the company's CEO, Jon Lambert, shared on the Houston Innovators Podcast.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.